Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to check if the transcript shows management speaking about customers/partners' own growth trajectories as the driver of Akoya's coming activity. Looking at the transcript, Brian McKelligon discusses: - The PhenoCycler-Fusion and PhenoImager HT platforms - New product launches (Discovery panels, signature panels, Fusion 2.0 upgrades) - CRO network expansion - Partnerships with Agilent, AstraZeneca, Acrivon - The Acrivon CDx partnership However, the discussion of counterparties is mostly about Akoya's own efforts to drive adoption, its own product launches, its own operational improvements. When discussing CROs and biopharma partners, it's about Akoya building the network and enabling them, not about those partners' own independent scaling trajectories driving Akoya's revenue. The Acrivon partnership is mentioned - "the continued productive advancement of our partnership with Acrivon" - but this is brief and not a substantial narration of Acrivon's own growth trajectory as the driver of Akoya's forward business. The discussion of customers is mostly about Akoya's efforts to increase pull-through, drive utilization, and expand its ecosystem - not about narrating specific counterparties' own ramps, launches, or build-outs as the reason for Akoya's coming volume. The forward account is driven by Akoya's own actions: new products, workflow improvements, operational efficiencies, cost programs. The counterparties (CROs, biopharma) are described as targets of Akoya's selling effort rather than parties whose own independent trajectories carry Akoya. This does not meet the criteria for YES. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.